MRSN
Closed
Mersana Therapeutics Inc
0.279
-0.017 (-5.74%)
Last Update: 01 Jul 2025 23:13:00
Yesterday: 0.296
Day's Range: 0.279 - 0.305
Send
sign up or login to leave a comment!
When Written:
4.48
Mersana Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) to treat cancer. The company's proprietary ADC platform, called Dolaflexin, enables the development of ADCs with enhanced efficacy and tolerability. Mersana's lead product candidate, XMT-1536, is a first-in-class ADC targeting NaPi2b, a protein that is overexpressed in multiple solid tumors. The company is also developing a pipeline of other ADCs targeting various cancer indications. Mersana is headquartered in Cambridge, Massachusetts and was founded in 2001. The company went public in 2017 and is traded on the NASDAQ stock exchange under the ticker symbol MRSN.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








